| [1] |
DU Chen, TIAN He, CAO Yang, WANG Yongjun, ZHANG Yan.
Research progress on bone metabolism disorders associated with PCOS elucidated from endocrine hormones
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 328-333.
|
| [2] |
SHI Yingzi, ZHAO Yang.
Impact of China-US drug regulatory incentives on local innovative drug simultaneous development in multiple countries: An empirical study based on zanubrutinib
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 560-569.
|
| [3] |
ZHANG Yanping, PEI Tong, HU Chaoying, ZHANG Lan.
Brief analysis on the measures for the management of instruments and equipment in phase Ⅰ drug clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 890-894.
|
| [4] |
ZHANG Xueting, ZHOU Xin, HU Xu, XIE Xuefeng.
Risk management of medication in transitional care
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 784-790.
|
| [5] |
JIANG Haihong, LI Xiao, LIU Yang.
Four dimensions of receiving overseas clinical trial data about drug and medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 835-840.
|
| [6] |
ZHANG Huimin, LIU Aiming, ZHU Wenfeng, YU Lingzhi, CHEN Fangliang.
Scientific decision process and regulation requirements based on the current guidelines of data extrapolation from adult to pediatric population
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 49-56.
|
| [7] |
WANG Lili.
Clinical application and rationality analysis of voriconazole injection
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 99-102.
|
| [8] |
LI Hao, CHENG Juan, ZHENG Xiaoqing, ZHANG Lei, ZHU Na, ZHOU Chengyue, WU Jian.
Establishment and application of DUE criteria for IV administration of voriconazole
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1420-1424.
|
| [9] |
LI Na, LIU Zhenyu, HU Wen, CHEN Chunlin.
Effects of Aztreonam combined Azithromycin on Pseudomonas aeruginosa bioflim
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1400-1405.
|
| [10] |
SHAN Jiao-jiao,TANG Yi-qun,SHI Mei-qi, XIA Guo-hao, WANG Li,FANG Ying,ZHAO Jie.
Impact of clinical pharmacists on protocol deviation in anti-cancer drug clinical trial
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 33-37.
|
| [11] |
LONG Hui-dong, LIN Yun-en, ZENG Zhao-hua, LIANG Li-ying, LAN Zhong, ZHANG Hai-jun.
Established a new rat model of metabolic syndrome
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1326-1329.
|
| [12] |
ZHANG Jian-ping, LOU Xiao-jie, ZHOU Yu-sheng.
Beijing anti-AIDS drug clinical trial case and particular protection to vulnerable persons as subjects
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(7): 832-836.
|
| [13] |
WANG Xiu-qin, XIONG Ning-ning, LIU Shen-lin, LI Qi-yi, JIANG Meng, LIU Fang, ZOU Jian-dong, GAO Wei-min, XUE Xue-kun.
Ethic review in clinical research:persons who are serving a sentence or receiving reeducation through labour
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(7): 837-840.
|
| [14] |
SHI Shao-jun, CHEN Hua-ting, ZENG Fan-dian.
Progress in research of pharmaceutical care
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(1): 1-4.
|
| [15] |
.
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1996, 1(1): 55-57.
|
